[journal]
Aaujo A
/ 2007
/ Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer—a review of the literature
/ Oncologist
12
: 201~210
[journal]
Ceppi P
/ 2006
/ ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
/ Ann Oncol
17
: 1818~1825
[journal]
Cappuzzo F
/ 2005
/ Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
/ J Natl Cancer Inst
97
: 643~655
[journal]
Chang TH
/ 2011
/ Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor
/ Am J Respir Crit Care Med
183
: 1071~1079
[journal]
Dougherty U
/ 2008
/ Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model
/ Clin Cancer Res
14
: 2253~2262
[journal]
Dziadziuszko R
/ 2006
/ Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non small cell lung cancer
/ Clin Cancer Res
12
: 3078~3084
[journal]
Eberhard DA
/ 2005
/ Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
/ J Clin Oncol
23
: 5900~5909
[journal]
Efferth T
/ 2007
/ From traditional Chinese medicine to rational cancer therapy
/ Trends Mol Med
13
: 353~361
[journal]
Fukuoka M
/ 2003
/ Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
/ J Clin Oncol
21
: 2237~2246
[journal]
Gomathinayagam R
/ 2008
/ Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells
/ Anticancer Res
28
: 785~792
[journal]
Guo H
/ 2011
/ Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy
/ Integr Cancer Ther
10
: 127~137
[journal]
Herbst RS
/ 2002
/ Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
/ J Clin Oncol
20
: 3815~3825
[journal]
Herbst RS
/ 2005
/ TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
/ J Clin Oncol
23
: 5892~5899
[journal]
Hirsch FR
/ 2007
/ Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
/ Ann Oncol
18
: 752~760
[journal]
Hirsch FR
/ 2008
/ Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
/ J Clin Oncol
26
: 3351~3357
[journal]
Huang S
/ 2004
/ Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor
/ Cancer Res
64
: 5355~5362
[journal]
Hynes NE
/ 2005
/ ERBB receptors and cancer: the complexity of targeted inhibitors
/ Nat Rev Cancer
5
: 341~354
[journal]
Janmaat ML
/ 2003
/ Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways
/ Clin Cancer Res
9
: 2316~2326
[journal]
Kelly K
/ 2008
/ Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor
/ J Thorac Oncol
3
: 664~673
[journal]
Kobayashi S
/ 2005
/ EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
/ N Engl J Med
352
: 786~792
[journal]
Kosaka T
/ 2004
/ Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications
/ Cancer Res
64
: 8919~8923
[journal]
Kwak EL
/ 2005
/ Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
/ Proc Natl Acad Sci USA
102
: 7665~7670
[journal]
Larco JEde
/ 1978
/ Growth factors from murine sarcoma virus-transformed cells
/ Proc Natl Acad Sci USA
75
: 4001~4005
[journal]
Lee JY
/ 2011
/ Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy
/ PLoS One
6
: e23756~
[journal]
Lentini A
/ 2010
/ Phytochemicals and proteinepolyamine conjugates by transglutaminase as chemopreventive and chemotherapeutic tools in cancer
/ Plant Physiol Biochem
48
: 627~633
[journal]
Lev-Ari S
/ 2006
/ Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity
/ Anticancer Res
26
: 4423~4430
[journal]
Maemondo M
/ 2010
/ Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR
/ N Engl J Med
362
: 2380~2388
[journal]
Marchetti A
/ 2005
/ EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
/ J Clin Oncol
23
: 857~865
[journal]
Misra R
/ 2010
/ Cancer nanotechnology: application of nanotechnology in cancer therapy
/ Drug Discov Today
15
: 842~850
[journal]
Mitsudomi T
/ 2005
/ Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
/ J Clin Oncol
23
: 2513~2520
[journal]
Mukherjee A
/ 2012
/ Ethanolic extract of Thuja occidentalis blocks proliferation of A549 cells and induces apoptosis in vitro
/ Zhong Xi Yi Jie He Xue Bao
10
: 1451~1459
[journal]
Normanno N
/ 2006
/ Epidermal growth factor receptor (EGFR) signaling in cancer
/ Gene
366
: 2~16
[journal]
Pao W
/ 2005
/ Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
/ PLoS One
2
: e73~
[journal]
Pollack VA
/ 1999
/ Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice
/ J Pharmacol Exp Ther
291
: 739~748
[journal]
Ramalingam S
/ 2008
/ Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions
/ Oncologist
13
: 5~13
[journal]
Rusnak DW
/ 2001
/ The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo
/ Mol Cancer Ther
1
: 85~94
[journal]
Schlessinger J
/ 2004
/ Common and distinct elements in cellular signaling via EGF and FGF receptors
/ Science
306
: 1506~1507
[journal]
Shan JZ
/ 2009
/ Ursolic acid inhibits proliferation and induces apoptosis of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway
/ J Zhejiang Univ Sci B
10
: 668~674
[journal]
Sharma SV
/ 2007
/ Epidermal growth factor receptor mutations in lung cancer
/ Nat Rev Cancer
7
: 169~181
[journal]
Tracy S
/ 2004
/ Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255
/ Cancer Res
64
: 7241~7244
[journal]
Traxler P
/ 2004
/ AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and anti-angiogenic activity
/ Cancer Res
64
: 4931~4941
[journal]
Tsou HR
/ 2005
/ Optimization of 6,7-disubstituted -4- (arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
/ J Med Chem
48
: 1107~1131
[journal]
Wakeling AE
/ 2002
/ ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
/ Cancer Res
62
: 5749~5754
[journal]
Weiss GJ
/ 2008
/ EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines
/ Ann Oncol
19
: 1053~1059
[journal]
Yarden Y
/ 2001
/ Untangling the ErbB signalling network
/ Nat Rev Mol Cell Biol
2
: 127~137
[journal]
Yun CH
/ 2007
/ Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity
/ Cancer Cell
11
: 217~227